论文部分内容阅读
目的:分析三才消哮饮治疗小儿哮喘缓解期的临床疗效。方法:对照组糖皮质激素-布地奈德气雾剂(普米克)进行治疗;治疗组在对照组基础上予以中药三才消哮饮治疗,4周为1个疗程,观察两组在3个月内的哮喘发作次数、上呼吸道感染次数、哮喘发作时的严重程度、总无喘息症状的天数和血浆皮质醇浓度的差别。结果:治疗4周后,治疗组在3个月内的哮喘发作次数、上呼吸道感染次数较对照低,差异明显(P<0.05);治疗组血浆皮质醇浓度与治疗前比较有明显升高,差异明显(P<0.05);与对照组比较,差异明显(P<0.05);总无喘息症状的天数和哮喘发作时的严重程度无差异(P>0.05)。结论:三才消哮饮治疗治疗小儿哮喘能减少哮喘发作次数、上呼吸道感染次数,升高血浆皮质醇浓度。值得临床推广使用。
Objective: To analyze the clinical efficacy of Sancai Xiaosi Yin in treating pediatric asthma remission. Methods: The control group of glucocorticoid budesonide aerosol (Pulmicort) for treatment; the treatment group in the control group based on the Chinese medicine Sancai Xiaoshu Yin treatment, 4 weeks for a course of treatment, the two groups were observed at 3 months The number of asthma attacks, the number of upper respiratory infections, the severity at the time of the asthma attack, the number of days with no wheezing symptoms, and the plasma cortisol concentration. Results: After 4 weeks of treatment, the numbers of asthma attacks and upper respiratory tract infections in the treatment group were significantly lower than those in the control group (P <0.05) within 3 months. The plasma cortisol levels in the treatment group were significantly higher than those before treatment, (P <0.05). Compared with the control group, the difference was significant (P <0.05). There was no difference in the number of days without wheezing and the severity of asthma attack (P> 0.05). Conclusion: Sancai Xiaojiangyin treatment for asthma in children can reduce the number of asthma attacks, the number of upper respiratory tract infections, increased plasma cortisol levels. It is worth to promote clinical use.